P2RY12 and acute coronary syndrome: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the cornerstone anti-thrombosis treatment for patients with acute coronary syndrome (ACS) who undergo stent implantation.Although the more potent P2Y12 inhibitor, ticagrelor, can significantly reduce the ischemic events in ACS patients compared to clopidogrel [1], the high bleeding risk and other side effects associated with ticagrelor have limited its clinical application [2, 3].